MCI | AD | |||
---|---|---|---|---|
Independent effects | OR IC95% | P | OR IC95% | p |
G (+) NO E4 (+) a | 0.90 (0.53-1.51) | 0.68 | 1.24 (0.74-2.08) | 0.42 |
E4 (+) b | 2.53 (1.69-3.79) | <0.001 | 4.37 (3.02-6.33) | <0.001 |
E4 (+)*Women b1 | 2.46 (1.45-4.15) | <0.001 | 5.10 (3.20-8.13) | <0.001 |
E4 (+)*Men b2 | 2.59 (1.36-4.92) | 0.04 | 3.19 (1.72-5.91) | <0.001 |
E4 (+) NO COMT_G b3 | 1.64 (0.80-3.36) | 0.18 | 2.61 (1.31-5.18) | <0.01 |
MCI | AD | |||
Synergistic effects | OR IC95% | p | OR IC95% | p |
E4 (+) * GG c | 2.11 (0.90-4.95) | 0.08 | 5.96 (2.74-12.94) | <0.001 |
E4 (+) * AG c | 3.21 (1.56-6.63) | 0.02 | 6.71 (3.36-13.41) | <0.001 |
E4 (+) * GG * WOMEN d | 2.00 (0.60-6.67) | 0.26 | 11.50 (3.83-34.53) | <0.001 |
E4 (+) * GG * MEN d | 3.30 (0.88-12.35) | 0.07 | 2.14 (0.64-7.20) | 0.22 |
E4 (+) * AG * WOMEN d | 2.40 (0.96-6.00) | 0.06 | 7.94 (3.24-19.42) | <0.001 |
E4 (+) * AG * MEN d | 5.88 (1.69-20.42) | <0.01 | 5.36 (1.76-16.28) | <0.01 |